title: No improvement in renal cell carcinoma survival: a population-based study in the Netherlands.
abstract: BACKGROUND
  The increased finding of kidney 'incidentalomas' and more frequent surgery in patients with renal cell cancer (RCC) metastases may have improved survival from the disease. However, recent data on survival of unselected population-based series of patients with RCC are sparse.
  
  
  METHODS
  We collected the follow-up data for all the patients registered with RCC in the population-based cancer registry held by the Comprehensive Cancer Centre East, the Netherlands.
  
  
  RESULTS
  Patients (1504) diagnosed with RCC between 1989 and 2002 were included. Eighty-three percent of all tumours were histologically confirmed; 17% of all diagnoses were based on clinical examination only. The latter group was older, had a worse stage distribution, often did not receive any kind of therapy and showed a 5-year relative survival of 8%. Five-year relative survival for patients with a histologically confirmed RCC was 60% and did not improve over the last 15 years. A low resection rate in patients with metastasis was observed, most pronounced in elderly, without a tendency of increase in more recent years.
  
  
  CONCLUSIONS
  The relative survival of RCC did not improve over the years. The resection rate in patients with metastasised disease did not increase over time, despite current knowledge concerning its benefit on tumour complications, time to progression and response to immunotherapy.
authors.affiliation: Comprehensive Cancer Centre East, Nijmegen, The Netherlands. K.Aben@iko.nl
authors.forename: K K H
authors.initials: KK
authors.lastname: Aben
authors.forename: T K
authors.initials: TK
authors.lastname: Luth
authors.forename: M L G
authors.initials: ML
authors.lastname: Janssen-Heijnen
authors.forename: P F
authors.initials: PF
authors.lastname: Mulders
authors.forename: L A
authors.initials: LA
authors.lastname: Kiemeney
authors.forename: D J
authors.initials: DJ
authors.lastname: van Spronsen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000401:mortality; D007680:Kidney Neoplasms / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods / Q000401:mortality; D009426:Netherlands / Q000453:epidemiology; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors